Anti-ARHGAP45 antibody (STJA0009676)
SPECIFICATIONS
ClonalityPolyclonal
HostRabbit
ConjugationUnconjugated
IsotypeIgG
ImmunogenSynthesized peptide derived from human HMHA1
General Information
| Short Description | Rabbit polyclonal anti-Rho GTPase-activating protein 45 for use in WB in Human and Mouse samples. Datasheet included with dilution recommendations, and related reagents. |
| Applications | WB |
| Host | Rabbit |
| Reactivity | Human/Mouse |
| Note | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Product Properties
| Clonality | Polyclonal |
| Isotype | IgG |
| Conjugation | Unconjugated |
| Concentration | 1 mg/mL |
| Purification | The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
| Dilution Range | WB 1:500-2000 |
| Formulation | Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide. |
| Storage Instruction | Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Target Information
| Gene Symbol | ARHGAP45 |
| Gene ID | 23526 |
| Uniprot ID | HMHA1_HUMAN |
| Immunogen | Synthesized peptide derived from human HMHA1 |
| Specificity | This antibody detects endogenous levels of HMHA1 at Human, Mouse |
Additional Info
| Function | Contains a GTPase activator for the Rho-type GTPases (RhoGAP) domain that would be able to negatively regulate the actin cytoskeleton as well as cell spreading. However, also contains N-terminally a BAR-domin which is able to play an autoinhibitory effect on this RhoGAP activity. Precursor of the histocompatibility antigen HA-1. More generally, minor histocompatibility antigens (mHags) refer to immunogenic peptide which, when complexed with MHC, can generate an immune response after recognition by specific T-cells. The peptides are derived from polymorphic intracellular proteins, which are cleaved by normal pathways of antigen processing. The binding of these peptides to MHC class I or class II molecules and its expression on the cell surface can stimulate T-cell responses and thereby trigger graft rejection or graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation from HLA-identical sibling donor. GVHD is a frequent complication after bone marrow transplantation (BMT), due to mismatch of minor histocompatibility antigen in HLA-matched sibling marrow transplants. Specifically, mismatching for mHag HA-1 which is recognized as immunodominant, is shown to be associated with the development of severe GVHD after HLA-identical BMT. HA-1 is presented to the cell surface by MHC class I HLA-A*0201, but also by other HLA-A alleles. This complex specifically elicits donor-cytotoxic T-lymphocyte (CTL) reactivity against hematologic malignancies after treatment by HLA-identical allogenic BMT. It induces cell recognition and lysis by CTL. |
| Protein Name | Rho Gtpase-Activating Protein 45 Cleaved Into - Minor Histocompatibility Antigen Ha-1Mhag Ha-1 |
| Database Links | Reactome: R-HSA-6798695Reactome: R-HSA-8980692Reactome: R-HSA-9013148Reactome: R-HSA-9013149 |
| Cellular Localisation | CytoplasmCell ProjectionRuffle Membrane |
| Alternative Antibody Names | Anti-Rho Gtpase-Activating Protein 45 Cleaved Into - Minor Histocompatibility Antigen Ha-1 antibodyAnti-Mhag Ha-1 antibodyAnti-ARHGAP45 antibodyAnti-HMHA1 antibodyAnti-KIAA0223 antibody |
Information sourced from Uniprot.org